Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  adenocarcinoma of the lung
Stage/Subtype:  adenocarcinoma of the lung
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 55 for your search:
Start Over
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NLG0301, NCI-2013-00592, 1209-1184, NCT01774578
Comparison of Different Types of Surgery in Treating Patients with Stage IA Non-Small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CALGB 140503, NCI-2009-00447, CDR0000555324, ECOG-40503, NCT00499330
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 20 and over
Trial IDs: U31287-A-U301, NCI-2014-01446, NCT02134015
Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A081105, NCI-2014-01508, CALGB A081105, NCT02193282
Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E4512, NCI-2014-01507, NCT02201992
Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1302.5, NCI-2016-00374, 2014-002161-30, NCT02272413
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5160C00007, NCI-2015-00219, 2014-002694-11, U1111-1160-2242, NCT02296125
A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130]
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GO29537, NCI-2015-01602, 2014-003206-32, NCT02367781
A Phase I/II Trial of Stereotactic Body Radiation Therapy (SBRT)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 06-0691 / 201012832, NCI-2011-00543, 06-0691, 201012832, NCT00591838
Panobinostat and Pemetrexed Disodium in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 08-036, NCI-2011-02483, NCT00907179
Veliparib with or without Radiation Therapy, Carboplatin, and Paclitaxel in Patients with Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1206, NCI-2011-02592, CDR0000701003, CHNMC-PHII-111, PHII-111, 8811, NCT01386385
Docetaxel With or Without MLN1117 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MLN1117-1501, NCI-2015-00520, 2014-004281-25, U1111-1160-1736, NCT02393209
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PCYC-1135-CA, NCI-2015-00591, NCT02403271
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NLG0401, NCI-2016-00186, 1504-1393, NCT02460367
Alectinib and Bevacizumab in Treating Patients with ALK-positive Stage IIIB-IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-055, NCI-2015-01704, NCT02521051
Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients with Stage III Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1106/ACRIN 6697, NCI-2012-00107, CDR0000721619, RTOG-1106, NCT01507428
Erlotinib Hydrochloride with or without Bevacizumab in Treating Patients with Stage IV Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RC1126, NCI-2012-00053, 11-006881, Mod11-006881-13, NCT01532089
Paclitaxel, Carboplatin, and Bevacizumab With or Without Metformin Hydrochloride in Treating Patients With Previously Untreated Stage IV Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1188, NCI-2012-00856, NA_00052073, NCT01578551
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients with Stage III Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 1306, NCI-2013-00737, NCT01822496
Sunitinib Malate in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Never Smoked
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-086, NCI-2013-01116, NCT01829217
Ponatinib Hydrochloride in Treating Patients with Stage III-IV Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-2002, NCI-2013-01644, PAM004-1, PAM005-2, NCT01935336
Start Over